Neuca

What Neuca does

NEUCA S.A. is Poland's largest pharmaceutical wholesale distributor, controlling approximately 30% of the wholesale-to-pharmacy market and serving nearly all of the country's pharmacies through a network of 15 modern distribution centers, including the state-of-the-art facility at Forteczna 35-37 in Toruń (the company's headquarters since 2020). The company serves independent pharmacies, pharmacy chains, hospitals, and NZOZ (outpatient healthcare facilities) via direct field sales, a telemarketing order center, and digital ordering platforms (NEUCA24, NEUCAapp). Crucially, NEUCA deliberately does not own any pharmacies — a conscious strategic choice that prevents channel conflict with its independent pharmacy customers, who participate in the Świat Zdrowia and Partner programs (1,977 participating pharmacies as of September 2025).

The company's revenue model is anchored in pharmaceutical wholesale distribution augmented by five growing verticals: own-brand products (Synoptis Pharma), private medical clinics (Świat Zdrowia — 87 owned facilities and 4,100 partner facilities), health insurance (TU Zdrowie, where NEUCA holds a dominant stake as of 2025), pharmaceutical manufacturing (P.P.H. EWA S.A. — 51.26% acquired in 2023; Global Pharma CM — acquired in 2025), and clinical research (Pratia/Clinscience/Humaneva Group — 100+ centers across 8 countries and 600+ active trials). The company also acts as AstraZeneca's exclusive pharmacy distribution agent in Poland since January 2023.

Founded in 1990 as TORFARM, the company has been listed on the Warsaw Stock Exchange (WSE: NEU) since 2004 and rebranded to NEUCA Group in 2010. It is controlled by founder Kazimierz Herba and his family. With 5,001-10,000 employees and 2024 revenue of 12.6 billion PLN (+6.8% YoY) and net profit of 171.6 million PLN, NEUCA is evolving from a pure-play wholesale distributor into a diversified healthcare platform with growing international clinical research footprint in the Czech Republic, Slovakia, Ukraine, Bulgaria, Germany, Spain, and the United States.

Name

Neuca

Legal name

NEUCA S.A.

Website

https://neuca.pl

Company type

Public

Founded year

1990

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

NEUCA S.A. is Poland's largest pharmaceutical wholesale distributor, holding approximately 30% market share and serving nearly all Polish pharmacies through 15 distribution centers. The diversified healthcare group also operates clinical research, medical clinics, health insurance, and pharmaceutical manufacturing businesses.

Ownership category

akta.pro rank

Product category

Pharmaceutical Wholesale Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Full-Line Pharmaceutical Wholesalers (HLAIAJAA)

akta.pro secondary industries

Retail Pharmacy Supply Wholesalers (HLAIAJAE), Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD)

Keywords

• Pharmaceutical wholesale distribution
• Clinical research services
• Pharmaceutical manufacturing
• Medical clinic services
• Private health insurance

Headquarters

HQ city

Torun

HQ country

Poland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Wholesale Distribution: Core business - pharmaceutical wholesale distribution to nearly all pharmacies in Poland, generating the majority of revenues. The company serves as the largest pharmaceutical distributor in Poland with approximately 30% market share in wholesale distribution to pharmacies.
2. Own Brand Products: Through Synoptis Pharma subsidiary, managing private label brands for pharmaceutical products
3. Medical Services: Revenue from medical clinics network (Świat Zdrowia) and health insurance services through TU Zdrowie S.A. The company operates 87 own medical facilities and 4,100 partner facilities as of September 2025.
4. Clinical Research Services: Through Humaneva Group (Pratia, Kapadi, Hyggio, Clinscience) - provides clinical trial services to pharmaceutical sponsors. Pratia operates over 100 centers in 8 countries with over 600 active clinical trials.
5. Pharmaceutical Manufacturing: Through P.P.H. EWA S.A. in Krotoszyn (acquired 51.26% in 2023) and Global Pharma CM - manufacturing pharmaceutical products, medical devices, and dietary supplements

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

NEUCA is Poland's largest pharmaceutical wholesale distributor, supplying medications to nearly all Polish pharmacies through 15 distribution centers and serving as AstraZeneca's exclusive pharmacy distribution agent. Beyond its core wholesale business, NEUCA operates clinical research services via the Humaneva Group (Pratia, Clinscience, OncoBay) across 8 countries, runs a medical clinic network (Świat Zdrowia) with 87 owned and 4,100 partner facilities, provides private health insurance (TU Zdrowie), and manufactures pharmaceuticals and dietary supplements through EWA S.A. and Global Pharma CM.

Product overview

NEUCA is a diversified healthcare group operating primarily as Poland's largest pharmaceutical wholesale distributor. The company operates on a platform-plus-services model, combining its core wholesale distribution business with complementary healthcare services. The product portfolio includes: (1) wholesale pharmaceutical distribution to nearly all Polish pharmacies through 15 distribution centers; (2) partnership programs for independent pharmacies under the Świat Zdrowia and Partner brands, providing business support tools; (3) clinical research operations through Pratia and the Humaneva Group ecosystem; (4) a network of medical clinics (Świat Zdrowia) with 87 owned and 4,100 partner facilities; (5) health insurance services through TU Zdrowie; (6) e-commerce platforms including Ortopedio.pl and digital ordering systems (NEUCA24, NEUCAapp); (7) telemedicine solutions including the Diabdis device for diabetes management; and (8) pharmaceutical manufacturing through acquired companies EWA and Global Pharma CM. The company deliberately does not own pharmacies to avoid competing with its customers.

Differentiator

Problem solved

Functional benefit

Brands

• Swiat Zdrowia: Medical clinics network and independent pharmacy partnership programs
• Pratia
• Humaneva
• Clinscience
• TU Zdrowie
• Farmaceuta
• NEUCA24
• NEUCAapp

Products and services

• Pharmaceutical Wholesale Distribution Wholesale distribution of pharmaceutical products to nearly all pharmacies in Poland through a network of 15 distribution centers; serves as AstraZeneca's exclusive pharmacy distribution agent in Poland since January 2023.
• Świat Zdrowia and Partner Pharmacy Partnership Programs Partnership programs for independent pharmacies providing business support tools, marketing resources, and exclusive benefits to help independent owners build competitiveness and profitability; 1,977 pharmacies participated as of September 2025.
• Clinical Research Services (Pratia / Humaneva Group) Clinical research site services to pharmaceutical sponsors across Poland, Czech Republic, Slovakia, Ukraine, Bulgaria, Germany, Spain, and the United States; operates over 100 sites with more than 600 active clinical trials in oncology and other therapeutic areas; includes Clinscience for data management and biostatistics.
• Świat Zdrowia Medical Clinics Network Network of outpatient medical clinics providing primary medical services to patients in Poland, with 87 owned facilities and 4,100 partner facilities as of September 2025.
• TU Zdrowie Private Health Insurance Private health insurance services providing healthcare coverage to Polish consumers, with NEUCA holding a dominant shareholding position as of 2025.
• NEUCA24 Online Ordering Platform Online ordering platform that enables pharmacy customers to place pharmaceutical orders, manage returns, and access refund lists (Moja Oferta module).
• NEUCAapp Mobile Ordering Application Mobile application enabling pharmacy customers to place orders and manage accounts from mobile devices.
• Pharmaceutical Manufacturing (P.P.H. EWA S.A.) Manufacture of pharmaceutical products, medical devices, and dietary supplements; acquired as a 51.26% stake in July 2023 with 2022 revenue of 52.3 million PLN.
• Global Pharma CM Contract Manufacturing Contract manufacturing services for medical devices, dietary supplements, and specialized food products; acquired by NEUCA in 2025 to support manufacturing capacity.
• Synoptis Pharma Own Brand Management Management of NEUCA's own pharmaceutical brands distributed through the wholesale channel; invested in by NEUCA in 2008.
• Diabdis Telemedicine Device Telemedicine device for diabetes management launched in 2016 as an innovative health monitoring product.
• Ortopedio.pl E-commerce Platform E-commerce platform for orthopedic products launched as part of NEUCA's digital commerce expansion.

Quantifiable outcome

• NEUCA achieved ~39% market share in the independent pharmacy segment in Q3 2025, the highest in company history
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• P1 TrialscoreStrategic or Co-development Partner · 8 December 2025Pratia from NEUCA Group invested in P1 Trials, a US organization specializing in early-phase oncology clinical trials. P1 Trials works with prominent oncology clinics in Washington, Texas, and Indiana states. The partnership creates a transatlantic clinical research network covering Europe and the United States.
• P.P.H. EWA S.A.coreStrategic or Co-development Partner · 19 July 2023NEUCA acquired 51.26% of P.P.H. EWA S.A. based in Krotoszyn, a manufacturer of pharmaceutical products, medical devices, and dietary supplements. 2022 revenue was 52.3 million PLN with net profit of 4.6 million PLN. Acquisition price was approximately 10.5 million PLN.
• Ryvu TherapeuticscoreStrategic or Co-development Partner · 14 July 2023Clinscience from NEUCA Group signed two agreements with Ryvu Therapeutics for data management and biostatistics services in Phase II clinical trials (RIVER-52 and RIVER-81) for RVU120 in hematology. Total contract value of 2.6 million EUR.
• AstraZenecacoreChannel Partner/ Reseller/ Distributor · 15 November 2022NEUCA serves as the exclusive agent for AstraZeneca products to pharmacies in Poland since January 2023. This follows AstraZeneca's decision to concentrate distribution to pharmacies through a single partner.
• KFGN (Klinische Forschungseinrichtungen)coreStrategic or Co-development Partner · 1 January 2020NEUCA acquired 40% stake in KFGN, the market leader for clinical research centers in Germany. This positioned Pratia to create the second-largest independent clinical research network in Europe.

Scale indicators14 records

Recent moves10 records

Expansion highlights8 records

Broad incumbents

• Cardinal Health: Global pharmaceutical and medical products distributor. Comparable as a wholesale distributor operating at massive scale with similar business model (full-line pharma wholesale to pharmacies and healthcare providers).
• IQVIA Holdings: Global clinical research and healthcare data giant. Comparable to NEUCA through Pratia/Humaneva clinical research operations and the broader CRO services market where Pratia competes for early-phase oncology and therapeutic trial contracts.
• Phoenix Group: European pharmaceutical wholesale leader headquartered in Germany. Comparable to NEUCA as the largest pharma wholesaler in its geography with similar full-line distribution model, manufacturer partnerships, and pharmacy customer base across multiple European countries.
• ICON plc: Global contract research organization providing clinical research services to pharmaceutical sponsors. Directly comparable to NEUCA's Pratia/Clinscience clinical research business in terms of CRO service offerings and customer base (pharma sponsors).
• Cencora (formerly AmerisourceBergen): Global pharmaceutical distribution giant (US-headquartered). Comparable to NEUCA's core wholesale business but at much larger scale, with similar full-line distribution model serving pharmacies, hospitals, and manufacturers with related services.

Regional players

• Polpharma S.A. Polish pharmaceutical manufacturer and one of the largest pharma companies in Central Europe. Comparable to NEUCA through its manufacturing arm (EWA/Global Pharma CM) and broader Polish pharma market presence, though Polpharma focuses on production rather than wholesale.

Others

• McKesson Corporation: Global pharmaceutical distribution leader (US-headquartered). Operates a large-scale pharma wholesale and distribution platform comparable to NEUCA's core business, though NEUCA is much smaller and Poland-focused.

Direct peers

• Pelion S.A. Polish pharmaceutical wholesale competitor operating in the same Polish market as NEUCA. Pelion (formerly Grupa Pelion) is one of the principal competitors in Polish pharma distribution, also serving pharmacies, hospitals, and retail chains with similar product range.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/grupa_neuca
• YouTubeyoutube.com/@grupaneuca6974
• Facebookfacebook.com/GrupaNEUCA
• LinkedInlinkedin.com/company/neuca-sa

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuca